Ip Christopher, Hall Simon J
Department of Urology, Mount Sinai School of Medicine, Box 1272, 1 Gustave L. Levy Place, New York, NY 10029, USA.
Endocrinol Metab Clin North Am. 2007 Jun;36(2):421-34. doi: 10.1016/j.ecl.2007.03.009.
In this article, the conflicting data concerning the androgen axis and prostate cancer development are reviewed in addition to how this pathway may be exploited to prevent the development of prostate cancer. The expanding role of hormone ablative therapy alone or in conjunction with standard therapies, the controversies of timing of therapy, and the completeness of ablation and its use on an intermittent basis are reviewed.